LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 213

Search options

  1. Article ; Online: Please eat me! Targeting CD47 and CD38 in T-ALL.

    Diorio, Caroline / Teachey, David T

    Blood

    2022  Volume 140, Issue 1, Page(s) 6–8

    MeSH term(s) Antibodies, Monoclonal ; CD47 Antigen ; Child ; Humans ; Immunotherapy ; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
    Chemical Substances Antibodies, Monoclonal ; CD47 Antigen ; CD47 protein, human ; daratumumab (4Z63YK6E0E)
    Language English
    Publishing date 2022-07-05
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2022016774
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Cytokine Storm Syndromes in Pediatric Patients.

    Diorio, Caroline / Teachey, David T / Canna, Scott W

    The journal of allergy and clinical immunology. In practice

    2023  Volume 11, Issue 6, Page(s) 1636–1644

    Abstract: Cytokine storm syndromes (CSS) represent a diverse group of disorders characterized by severe overactivation of the immune system. In the majority of patients, CSS arise from a combination of host factors, including genetic risk and predisposing ... ...

    Abstract Cytokine storm syndromes (CSS) represent a diverse group of disorders characterized by severe overactivation of the immune system. In the majority of patients, CSS arise from a combination of host factors, including genetic risk and predisposing conditions, and acute triggers such as infections. CSS present differently in adults than in children, who are more likely to present with monogenic forms of these disorders. Individual CSS are rare, but in aggregate represent an important cause of severe illness in both children and adults. We present 3 rare, illustrative cases of CSS in pediatric patients that describe the spectrum of CSS.
    MeSH term(s) Humans ; Child ; COVID-19/complications ; SARS-CoV-2 ; Cytokine Release Syndrome ; Cytokines ; Immune System
    Chemical Substances Cytokines
    Language English
    Publishing date 2023-03-27
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2023.03.033
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax.

    Niswander, Lisa M / Chung, Perry / Diorio, Caroline / Tasian, Sarah K

    Haematologica

    2023  Volume 108, Issue 11, Page(s) 3142–3147

    MeSH term(s) Humans ; Child ; Azacitidine/therapeutic use ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Sulfonamides/therapeutic use ; Leukemia/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Leukemia, Myeloid, Acute/drug therapy
    Chemical Substances Azacitidine (M801H13NRU) ; venetoclax (N54AIC43PW) ; Bridged Bicyclo Compounds, Heterocyclic ; Sulfonamides
    Language English
    Publishing date 2023-11-01
    Publishing country Italy
    Document type Letter
    ZDB-ID 2333-4
    ISSN 1592-8721 ; 0017-6567 ; 0390-6078
    ISSN (online) 1592-8721
    ISSN 0017-6567 ; 0390-6078
    DOI 10.3324/haematol.2022.282637
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Need for standardization of cytokine profiling in CAR T cell therapy.

    Biery, D Nathan / Turicek, David P / Diorio, Caroline / Schroeder, Brett A / Shah, Nirali N

    Molecular therapy : the journal of the American Society of Gene Therapy

    2024  

    Abstract: With expansion of chimeric antigen receptor (CAR) T cell therapy and broader utilization of anti-cytokine directed therapeutics for toxicity mitigation, the routine assessment of cytokines may enhance understanding of toxicity profiles, guide therapeutic ...

    Abstract With expansion of chimeric antigen receptor (CAR) T cell therapy and broader utilization of anti-cytokine directed therapeutics for toxicity mitigation, the routine assessment of cytokines may enhance understanding of toxicity profiles, guide therapeutic interventions, and facilitate cross-trial comparisons. As specific cytokine elevations can correlate with and provide insights into CAR T cell toxicity, mitigation strategies, and response, we explored the reporting of cytokine detection methods and assessed for the correlation of cytokines to cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) across clinical trials. In this analysis, we reviewed 21 clinical trials across 60 manuscripts that featured a US Food and Drug Administration-approved CAR T cell construct or one of its predecessors. We highlight substantial variability and limited reporting of cytokine measurement platforms and panels used across CAR T cell clinical trials. Specifically, across 60 publications, 28 (46.7%) did not report any cytokine data, representing 6 of 21 (28.6%) clinical trials. In the 15 trials reporting cytokine data, at least 4 different platforms were used. Furthermore, correlation of cytokines with ICANS, CRS, and CRS severity was limited. Considering the fundamental role of cytokines in CAR T cell toxicity, our manuscript supports the need to establish standardization of cytokine measurements as a key biomarker essential to improving outcomes of CAR T cell therapy.
    Language English
    Publishing date 2024-03-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2010592-7
    ISSN 1525-0024 ; 1525-0016
    ISSN (online) 1525-0024
    ISSN 1525-0016
    DOI 10.1016/j.ymthe.2024.03.030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Analyse des effets des inhibiteurs de l’aromatase en traitement prolongé chez les femmes ménopausées atteintes d’un cancer du sein non métastatique hormonodépendant ayant déjà reçu cinq ans d’hormonothérapie adjuvante : revue systématique et méta-analyse.

    Trenou, Kossi Clément / Mésidor, Miceline / Diorio, Caroline / Eslami, Aida / Talbot, Denis

    Bulletin du cancer

    2024  Volume 111, Issue 4, Page(s) 356–362

    Abstract: Introduction: Evaluating the benefits and risks of prolonged hormonal treatment with aromatase inhibitors (AIs) for treating hormone-dependent breast cancer.: Methods: A systematic review and meta-analysis was conducted. Studies reporting on ... ...

    Title translation Effects of extended aromatase inhibitors in women with hormone-dependent breast cancer who have already received five years of adjuvant hormone therapy: A systematic review and meta-analysis.
    Abstract Introduction: Evaluating the benefits and risks of prolonged hormonal treatment with aromatase inhibitors (AIs) for treating hormone-dependent breast cancer.
    Methods: A systematic review and meta-analysis was conducted. Studies reporting on randomized clinical trials concerning prolongating hormonal therapy with AIs as compared to a placebo or no prolongation, after an initial five years of hormonal therapy, were eligible.
    Results: Seven clinical trials were included. Prolonged AI therapy was associated with a statistically significant improvement in disease-free survival (RR=0.70, 95% CI 0.60 to 0.80). A statistically significant increase was observed for osteoporosis (RR=1.17, 95% CI 1.03 to 1.33), hot flushes/flashes (RR=1.27, 95% CI 1.08 to 1.49), myalgia (RR=1.23, 95% CI 1.09 to 1.39), fractures (RR=1.26, 95% CI 1.09 to 1.45) and arthralgia (RR=1.17, 95% CI 1.10 to 1.25). However, no statistically significant association was observed between prolonged AI therapy and overall survival, cardiovascular events, and bone pain.
    Discussion: Prolonged AI therapy has significant benefits in terms of disease-free survival in women with hormone-dependent breast cancer. However, adverse effects and a lack of evidence for a benefit on overall survival must be considered in the decision-making process regarding adjuvant hormone therapy extension.
    MeSH term(s) Female ; Humans ; Breast Neoplasms/drug therapy ; Aromatase Inhibitors/adverse effects ; Combined Modality Therapy ; Chemotherapy, Adjuvant/adverse effects ; Adjuvants, Immunologic/therapeutic use ; Hormones/therapeutic use ; Antineoplastic Agents, Hormonal/adverse effects ; Tamoxifen/adverse effects
    Chemical Substances Aromatase Inhibitors ; Adjuvants, Immunologic ; Hormones ; Antineoplastic Agents, Hormonal ; Tamoxifen (094ZI81Y45)
    Language French
    Publishing date 2024-03-06
    Publishing country France
    Document type Meta-Analysis ; Systematic Review ; English Abstract ; Journal Article
    ZDB-ID 213270-9
    ISSN 1769-6917 ; 0007-4551
    ISSN (online) 1769-6917
    ISSN 0007-4551
    DOI 10.1016/j.bulcan.2023.12.016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Double robust estimation of optimal partially adaptive treatment strategies: An application to breast cancer treatment using hormonal therapy.

    Talbot, Denis / Moodie, Erica E M / Diorio, Caroline

    Statistics in medicine

    2022  Volume 42, Issue 2, Page(s) 178–192

    Abstract: Precision medicine aims to tailor treatment decisions according to patients' characteristics. G-estimation and dynamic weighted ordinary least squares are double robust methods to identify optimal adaptive treatment strategies. It is underappreciated ... ...

    Abstract Precision medicine aims to tailor treatment decisions according to patients' characteristics. G-estimation and dynamic weighted ordinary least squares are double robust methods to identify optimal adaptive treatment strategies. It is underappreciated that they require modeling all existing treatment-confounder interactions to be consistent. Identifying optimal partially adaptive treatment strategies that tailor treatments according to only a few covariates, ignoring some interactions, may be preferable in practice. Building on G-estimation and dWOLS, we propose estimators of such partially adaptive strategies and demonstrate their double robustness. We investigate these estimators in a simulation study. Using data maintained by the Centre des Maladies du Sein, we estimate a partially adaptive treatment strategy for tailoring hormonal therapy use in breast cancer patients. R software implementing our estimators is provided.
    MeSH term(s) Humans ; Female ; Models, Statistical ; Breast Neoplasms/drug therapy ; Computer Simulation ; Precision Medicine/methods ; Software
    Language English
    Publishing date 2022-11-21
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 843037-8
    ISSN 1097-0258 ; 0277-6715
    ISSN (online) 1097-0258
    ISSN 0277-6715
    DOI 10.1002/sim.9608
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Sleep quality traits correlate with inflammatory markers in the breast tissue of women.

    Chang, Sue-Ling / Durocher, Francine / Diorio, Caroline

    Cytokine

    2022  Volume 160, Page(s) 156028

    Abstract: Background: Several mechanisms have been posited to play a role in the sleep and breast cancer association, including alterations in immune function, but evidence remains inconclusive. A closer look at how sleep quality traits affect the breast ... ...

    Abstract Background: Several mechanisms have been posited to play a role in the sleep and breast cancer association, including alterations in immune function, but evidence remains inconclusive. A closer look at how sleep quality traits affect the breast microenvironment may provide clues for molecular mechanisms underlying the link between sleep and breast cancer. We examined the association between sleep quality traits (sleep duration, sleep aids, and insomnia) and tissue-based protein levels and gene expression of several inflammatory markers associated with breast cancer.
    Methods: Breast tissues (normal n = 165 and adipose n = 74) were surgically obtained from women diagnosed with breast cancer. Protein levels by immunohistochemistry were determined using the quickscore method for 11 inflammatory markers in the normal epithelial breast tissue (interleukin (IL)-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), cyclooxygenase-2 (COX-2), leptin, serum amyloid A1 (SAA1), lactoferrin, transforming growth factor-beta (TGF-β), and signal transducer and activator of transcription 3 markers (STAT3). Relative quantification of 4 genes (COX-2, IL-6, TNF-α and LEP) in the adipose breast tissue was carried out using qPCR. Patient characteristics and sleep traits (average sleep duration per night, taking sleeping aids in the past year, and the average number of insomnia episodes per month) were determined by telephone interview. Associations were tested using Spearman's rank correlation (r<sub>s</sub>) coefficients adjusted (ar<sub>s</sub>) for age at surgery, menopausal status and PCR batch when applicable. Sleep duration categories (<7, 7-9, >9 h) and root- or log-transformed biomarker levels were examined with adjusted linear mixed models.
    Results: TGF-β and CRP levels in normal epithelial breast tissue were positively correlated with sleep aids (ar<sub>s</sub> = 0.28, p = 0.013), and insomnia (ar<sub>s</sub> = 0.23, p = 0.044) in postmenopausal women, respectively. IL-6 in the adipose breast tissue was inversely correlated with sleep aids (ar<sub>s</sub> = -0.26, p = 0.029) in all women. None of the sleep traits significantly correlated with inflammatory markers in premenopausal women. Several markers tended to correlate at 0.05 ≥ p ≤ 0.10. Adjusted mean levels of inflammatory markers were significantly different across sleep duration categories (<7, 7-9, >9 h). Higher mean levels of IL-6, CRP, IL-10, and IL-6 and COX-2 expression were noted in the breast tissues of women sleeping < 7, and particularly, >9 h per night (p < 0.05).
    Conclusion: Our findings indicate that sleep duration, sleep aids, and insomnia may differently affect women's breast tissues depending on menopausal status. From a public health perspective, these results warrant further validation in larger studies. Since sleep is a modifiable factor, it may be an interesting approach for breast cancer prevention.
    MeSH term(s) Acquired Immunodeficiency Syndrome ; Biomarkers ; Breast Neoplasms/pathology ; C-Reactive Protein/metabolism ; Cyclooxygenase 2/metabolism ; Female ; Humans ; Interleukin-10/metabolism ; Interleukin-6 ; Interleukin-8/metabolism ; Lactoferrin ; Leptin/metabolism ; STAT3 Transcription Factor/metabolism ; Sleep Initiation and Maintenance Disorders ; Sleep Quality ; Transforming Growth Factor beta/metabolism ; Transforming Growth Factors ; Tumor Necrosis Factor-alpha/metabolism
    Chemical Substances Biomarkers ; Interleukin-6 ; Interleukin-8 ; Leptin ; STAT3 Transcription Factor ; Transforming Growth Factor beta ; Tumor Necrosis Factor-alpha ; Interleukin-10 (130068-27-8) ; Transforming Growth Factors (76057-06-2) ; C-Reactive Protein (9007-41-4) ; Cyclooxygenase 2 (EC 1.14.99.1) ; Lactoferrin (EC 3.4.21.-)
    Language English
    Publishing date 2022-09-11
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1018055-2
    ISSN 1096-0023 ; 1043-4666
    ISSN (online) 1096-0023
    ISSN 1043-4666
    DOI 10.1016/j.cyto.2022.156028
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: CAR T cells vs allogeneic HSCT for poor-risk ALL.

    Diorio, Caroline / Maude, Shannon L

    Hematology. American Society of Hematology. Education Program

    2020  Volume 2020, Issue 1, Page(s) 501–507

    Abstract: For subgroups of children with B-cell acute lymphoblastic leukemia (B-ALL) at very high risk of relapse, intensive multiagent chemotherapy has failed. Traditionally, the field has turned to allogeneic hematopoietic stem cell transplantation (HSCT) for ... ...

    Abstract For subgroups of children with B-cell acute lymphoblastic leukemia (B-ALL) at very high risk of relapse, intensive multiagent chemotherapy has failed. Traditionally, the field has turned to allogeneic hematopoietic stem cell transplantation (HSCT) for patients with poor outcomes. While HSCT confers a survival benefit for several B-ALL populations, often HSCT becomes standard-of-care in subsets of de novo ALL with poor risk features despite limited or no data showing a survival benefit in these populations, yet the additive morbidity and mortality can be substantial. With the advent of targeted immunotherapies and the transformative impact of CD19-directed chimeric antigen receptor (CAR)-modified T cells on relapsed or refractory B-ALL, this approach is currently under investigation in frontline therapy for a subset of patients with poor-risk B-ALL: high-risk B-ALL with persistent minimal residual disease at the end of consolidation, which has been designated very high risk. Comparisons of these 2 approaches are fraught with issues, including single-arm trials, differing eligibility criteria, comparisons to historical control populations, and vastly different toxicity profiles. Nevertheless, much can be learned from available data and ongoing trials. We will review data for HSCT for pediatric B-ALL in first remission and the efficacy of CD19 CAR T-cell therapy in relapsed or refractory B-ALL, and we will discuss an ongoing international phase 2 clinical trial of CD19 CAR T cells for very-high-risk B-ALL in first remission.
    MeSH term(s) Adolescent ; Allografts ; Female ; Hematopoietic Stem Cell Transplantation ; Humans ; Immunotherapy, Adoptive ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/metabolism ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Risk Factors
    Language English
    Publishing date 2020-12-04
    Publishing country United States
    Document type Case Reports ; Comparative Study ; Journal Article ; Review
    ZDB-ID 2084287-9
    ISSN 1520-4383 ; 1520-4391
    ISSN (online) 1520-4383
    ISSN 1520-4391
    DOI 10.1182/hematology.2020000172
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Harnessing immunotherapy for pediatric T-cell malignancies.

    Diorio, Caroline / Teachey, David T

    Expert review of clinical immunology

    2020  Volume 16, Issue 4, Page(s) 361–371

    Abstract: Pediatric T-cell hematologic malignancies are a diverse group of rare cancers. The most common pediatric T-cell malignancies include T-cell acute lymphoblastic leukemia (T-ALL) and anaplastic large cell lymphoma (ALCL). Although the overall survival ... ...

    Abstract Pediatric T-cell hematologic malignancies are a diverse group of rare cancers. The most common pediatric T-cell malignancies include T-cell acute lymphoblastic leukemia (T-ALL) and anaplastic large cell lymphoma (ALCL). Although the overall survival rates have improved markedly in recent years, children with relapsed T-ALL and ALCL have very low rates of cure and few salvage therapies exist. Current treatment regimens rely on toxic chemotherapies with significant short- and long-term morbidity. Immunotherapies, including antibodies and adoptive cellular therapies, have revolutionized the treatment of B-cell malignancies in pediatrics. The adaptation of these therapies to T-cell malignancies has been slower because of challenges implicit in the design and implementation of immunotherapies for T-cell malignancies, including the potential risks of fratricide, immunosuppression, and graft versus host disease (GVHD). We present a review of current challenges in the development of immunotherapies for T-cell hematologic malignancies, potential solutions and therapies under investigation. We include a particular focus on T-ALL and ALCL. Immunotherapies offer promising strategies to improve outcomes in children with T-cell malignancies, particularly in the setting of relapse. Optimizing efficacy, mitigating toxicity, and safely integrating with conventional therapies are key considerations as immunotherapies are translated into the clinic.
    MeSH term(s) Child ; Hematologic Neoplasms/immunology ; Hematologic Neoplasms/therapy ; Humans ; Immunosuppression Therapy ; Immunotherapy, Adoptive/methods ; T-Lymphocytes/immunology
    Language English
    Publishing date 2020-02-27
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 2274260-8
    ISSN 1744-8409 ; 1744-666X
    ISSN (online) 1744-8409
    ISSN 1744-666X
    DOI 10.1080/1744666X.2020.1732819
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Breast Cancer Treatments: Updates and New Challenges.

    Burguin, Anna / Diorio, Caroline / Durocher, Francine

    Journal of personalized medicine

    2021  Volume 11, Issue 8

    Abstract: Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B, HER2 and triple-negative breast cancer (TNBC)) according to the expression of ... ...

    Abstract Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B, HER2 and triple-negative breast cancer (TNBC)) according to the expression of the estrogen receptor (ER) and the progesterone receptor (PR), and the overexpression of the human epidermal growth factor receptor 2 (HER2). Current BC treatments target these receptors (endocrine and anti-HER2 therapies) as a personalized treatment. Along with chemotherapy and radiotherapy, these therapies can have severe adverse effects and patients can develop resistance to these agents. Moreover, TNBC do not have standardized treatments. Hence, a deeper understanding of the development of new treatments that are more specific and effective in treating each BC subgroup is key. New approaches have recently emerged such as immunotherapy, conjugated antibodies, and targeting other metabolic pathways. This review summarizes current BC treatments and explores the new treatment strategies from a personalized therapy perspective and the resulting challenges.
    Language English
    Publishing date 2021-08-19
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2662248-8
    ISSN 2075-4426
    ISSN 2075-4426
    DOI 10.3390/jpm11080808
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top